Puma Biotechnology Inc (PBYI) Jumps 5.38% on February 19

Equities Staff |

Puma Biotechnology Inc (PBYI) was among the biggest gainers on the Russell 2000 for Friday February 19 as the stock popped 5.38% to $46.60, representing a gain of $2.38 per share. Some 434,942 shares traded hands on 4,085 trades, compared with an average daily volume of 800,488 shares out of a total float of 32.44 million. The stock opened at $43.78 and traded with an intraday range of $46.65 to $43.77.

After today's gains, Puma Biotechnology Inc reached a market cap of $1.51 billion. Puma Biotechnology Inc has had a trading range between $252.92 and $34.71 over the last year, and it had a 50-day SMA of $57.64 and a 200-day SMA of $94.61.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 120 employees. Its CEO is Alan H. Auerbach.

For a complete fundamental analysis analysis of Puma Biotechnology Inc, check out Equities.com’s Stock Valuation Analysis report for PBYI. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…


Airbnb is a community marketplace for people to list, discover, and book unique accommodations around the world — online or from a mobile phone. Whether an apartment for a night,…